Basildon Hospital is using calprotectin home testing to support IBD patients. Kezia Allen, Associate Practitioner, Clinical Trials, Basildon Hospital, reveals the feedback from patients who are using calprotectin tests, as well as some key considerations for the Trust.
The demands on healthcare resources continue to escalate, with the COVID pandemic having exacerbated the existing pressures from an ageing population living longer and with more complex health conditions. Changes to traditional practices are essential if healthcare services are to keep pace with the increased demands.
Developments in digital App technology have the ability to not only improve the health of patients, but also to save money, through rapid optimisation of treatment. They enable early interventions through monitoring, before conditions get too serious and reduce the need for routine check-up appointments and procedures. This frees up limited resources in both pathology and the clinic
The Bühlmann IBDoc was one of the first calprotectin home tests to be introduced to the market back in 2015. Since then, there have been numerous publications demonstrating the correlation of the IBDoc result from the test performed by the patient in their own home, to the results of professional laboratory analyses. More importantly there is also evidence of the correlation to the IBDoc calprotectin results to the endoscopic and histologic findings of disease status. The test meets demand from a clinical perspective, therefore
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.
